Top Suppliers:I want be here
Related CAS#:
577953-88-9 68835-87-0
1329611-20-2 76698-56-1
30924-91-5 88463-00-7
88463-02-9 110637-41-7
61315-59-1 115491-98-0
1823314-44-8 1934530-14-9
2100294-08-2 14523-98-9
2027674-80-0 80868-64-0
2018557-13-4 1456890-45-1
1849295-28-8 2003657-54-1

577953-88-9

577953-88-9 structure
577953-88-9 structure
  • Name: Montelukast Dicyclohexylamine Salt
  • Chemical Name: 1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt
  • CAS Number: 577953-88-9
  • Molecular Formula: C47H59ClN2O3S
  • Molecular Weight: 767.501
  • Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2024-01-09 10:02:20
  • Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research[1][2][3][4].
Name 1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt
Synonyms Montelukast Dicyclohexylamine Salt
Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, compd. with N-cyclohexylcyclohexanamine (1:1)
{1-[({(1R)-1-{3-[(E)-2-(7-Chloro-2-quinolinyl)vinyl]phenyl}-3-[2-(2-hydroxy-2-propanyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid - N-cyclohexylcyclohexanamine (1:1)
Description Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research[1][2][3][4].
Related Catalog
Target

CysLT1

In Vitro Montelukast (5 μM; 1 h) inhibits APAP (Acetaminophen) (HY-66005)-induced cell damage[1]. Montelukast (0.01-10 μM, 30 min) diminishes the 5-oxo-ETE–induced cell migration and modulates the activation of the plasmin-plasminogen system[3]. Montelukast (10 μM, 18 h) modulates the activation of MMP-9[3]. Cell Migration Assay [3] Cell Line: Eosinophils Concentration: 0.01-10 μM Incubation Time: 30 min Result: Diminished the 5-oxo-ETE–induced cell migration. Western Blot Analysis[3] Cell Line: Eosinophils Concentration: 10 μM Incubation Time: 18 h Result: Reduced the 5-oxo-ETE–boosted MMP-9 secretion.
In Vivo Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice[1]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2]. Animal Model: C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1] Dosage: 3 mg/kg Administration: Oral gavage 1 h after saline or APAP administration Result: Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.
References

[1]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.

[2]. William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16.

[3]. Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118(1):113-119.

[4]. Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59(4):780-786.
Melting Point 65-67°C (lit.)
Molecular Formula C47H59ClN2O3S
Molecular Weight 767.501
Exact Mass 766.393494
PSA 107.75000
LogP 12.58030
Storage condition 2-8°C
Hazard Codes Xi
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:577953-88-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 577953-88-9 | Chemsrc address: https://m.chemsrc.com/en/baike/1085144.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved